Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Ben Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-3602-4924; OpenAlex author ID A5007202153, A5121501372. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 6 papers · 2026: 2 papers

Papers 11

  1. Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41467-026-77665-z↗
  2. Dual-energy CT extracellular volume fraction for predicting the chemotherapeutic response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40644-026-01110-z↗
  3. Multiparametric MRI for Assessment of the Biological Invasiveness and Prognosis of Pancreatic Ductal Adenocarcinoma in the Era of Artificial Intelligence. Co-author DOI 10.1002/jmri.29708↗
  4. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.115541↗
  5. Targeted intervention in nerve-cancer crosstalk enhances pancreatic cancer chemotherapy. Co-author DOI 10.1038/s41565-024-01803-1↗
  6. Engineering a spatiotemporal macrophage circuit via STING phase separation to override immune suppression in pancreatic cancer. Co-author DOI 10.1073/pnas.2504718122↗
  7. A radiomics-based model for predicting lymph nodes metastasis of pancreatic ductal adenocarcinoma: a multicenter study. First author DOI 10.1186/s13244-025-02025-2↗
  8. The Tumor-Suppressive Role of SAT2 in Pancreatic Cancer: Involvement in PI3K/Akt-MAPK Pathways and Immune Modulation. Co-author DOI 10.3390/cimb47100872↗
  9. Signal enhancement ratio of multi-phase contrast-enhanced MRI: an imaging biomarker for survival in pancreatic adenocarcinoma. Co-author DOI 10.1007/s00330-024-10746-z↗
  10. Development of a radiomics-based model to predict occult liver metastases of pancreatic ductal adenocarcinoma: a multicenter study. Co-author DOI 10.1097/js9.0000000000000908↗
  11. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Co-author DOI 10.1038/s41420-020-0246-7↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shenghong Ju 居胜红 · 7 shared papers, 2024–2026 · strength 1.40
  2. Liwen Zhu · 4 shared papers, 2024–2026 · strength 0.82
  3. Cong Xia · 3 shared papers, 2024–2025 · strength 0.53
  4. Shuai Ming · 2 shared papers, 2026 · strength 0.46
  5. Lu Zhang · 1 shared paper, 2025 · strength 0.33
  6. Marija Trajkovic‐Arsic · 2 shared papers, 2020–2025 · strength 0.30
  7. Stephan A. Hahn · 2 shared papers, 2020–2025 · strength 0.30
  8. Jens Thomas Siveke · 2 shared papers, 2020–2025 · strength 0.30
  9. Smiths Lueong · 2 shared papers, 2020–2025 · strength 0.30
  10. Dan Shi · 1 shared paper, 2026 · strength 0.26
  11. Hongji Zhu · 1 shared paper, 2026 · strength 0.26
  12. Wei Wei · 1 shared paper, 2026 · strength 0.26
  13. Xin Li · 1 shared paper, 2025 · strength 0.21
  14. Jianqiong Zhang · 1 shared paper, 2025 · strength 0.21
  15. Xue Yang · 1 shared paper, 2025 · strength 0.21
  16. Lu Gan · 1 shared paper, 2025 · strength 0.21
  17. Xiaoyuan Shawn Chen · 1 shared paper, 2025 · strength 0.21
  18. Gao‐Jun Teng · 1 shared paper, 2025 · strength 0.21
  19. Shanmiao Gou · 1 shared paper, 2025 · strength 0.21
  20. Jiaqi Qin · 1 shared paper, 2025 · strength 0.21
  21. Yuling Sun · 1 shared paper, 2025 · strength 0.21
  22. Wei Wei · 1 shared paper, 2026 · strength 0.20
  23. Rui Fang · 1 shared paper, 2025 · strength 0.20
  24. Madeleine Dorsch · 1 shared paper, 2025 · strength 0.20
  25. Qi Zhang · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.